(NASDAQ: HALO) Halozyme Therapeutics's forecast annual revenue growth rate of 14.41% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Halozyme Therapeutics's revenue in 2024 is $862,989,000.On average, 5 Wall Street analysts forecast HALO's revenue for 2024 to be $121,268,067,214, with the lowest HALO revenue forecast at $120,660,842,960, and the highest HALO revenue forecast at $121,852,127,600. On average, 6 Wall Street analysts forecast HALO's revenue for 2025 to be $141,012,210,108, with the lowest HALO revenue forecast at $135,062,786,978, and the highest HALO revenue forecast at $153,298,987,520.
In 2026, HALO is forecast to generate $165,539,055,374 in revenue, with the lowest revenue forecast at $162,482,442,990 and the highest revenue forecast at $169,414,421,400.